Target intelligence / Profile preview

Ribosomal translation machinery (80S ribosome and eukaryotic release factors eRF1 and eRF3)

Molecular classification
Ribonucleoprotein complex, Translation factor, Enzyme, GTPase (eRF3), Hydrolase (eRF1)
01

Overview

The ribosomal translation machinery at CGA-derived nonsense codons refers to the assembly of the 80S ribosome and eukaryotic release factors (eRF1 and eRF3) at premature termination codons (PTCs) that originate from mutations in the CGA arginine codon. In the human genome, CGA is a hypermutable hot spot because it contains a CpG dinucleotide; deamination of the methylated cytosine frequently converts CGA to TGA (UGA in mRNA), making it the most common source of nonsense mutations in genetic diseases. When the translation machinery encounters such a PTC, it typically terminates protein synthesis, leading to truncated, nonfunctional proteins and triggering nonsense-mediated mRNA decay (NMD). This machinery is a critical therapeutic target for nonsense suppression (readthrough) agents like ataluren and aminoglycosides. These drugs bind to the ribosomal decoding center and reduce the stringency of codon recognition, allowing the insertion of a near-cognate amino acid at the PTC and enabling the production of full-length, functional proteins. This therapeutic strategy is being applied to various conditions, including Duchenne muscular dystrophy, cystic fibrosis, and cancers with nonsense mutations in tumor suppressor genes. Additionally, in certain organisms like Saccharomyces cerevisiae, the CGA codon itself can be misdecoded as a stop codon by this machinery, serving as a model for studying ribosome stalling and rescue pathways.

Other names
Translation termination complexNonsense suppression machineryRibosome-eRF1-eRF3 complexCGA-derived nonsense codon translation machineryRibosomal decoding centerPremature termination codon (PTC) readthrough machinery
02

Mechanism of action

Nonsense suppression or translational readthrough, where small molecules bind to the ribosomal decoding center (A-site) to decrease the fidelity of codon-anticodon pairing, allowing the insertion of a near-cognate aminoacyl-tRNA at a premature termination codon instead of recruiting release factors.

03

Biological functions

Translation terminationProtein synthesisNonsense-mediated mRNA decay (NMD)Ribosome rescueTranslational readthrough
04

Disease associations

Duchenne muscular dystrophy (DMD)Cystic fibrosisCancer (e.g., TP53 nonsense mutations)HemophiliaAniridiaSpinal muscular atrophyBeta-thalassemia
05

Safety considerations

Aminoglycoside-induced ototoxicityAminoglycoside-induced nephrotoxicityPotential for global readthrough of natural stop codonsInterference with normal translation termination fidelity
06

Interacting drugs

Ataluren (PTC124)

6 more in the full profile.

07

Biomarkers

Full-length protein expression (e.g., Dystrophin)mRNA stability (NMD escape)CFTR chloride channel functionp53 protein levelsAminoglycoside serum levels

Beyond the preview

Go deeper on Ribosomal translation machinery (80S ribosome and eukaryotic release factors eRF1 and eRF3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal translation machinery (80S ribosome and eukaryotic release factors eRF1 and eRF3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call